Non Vitamin k Antagonist Oral Anticoagulation Assessment in Non Valvular Atrial Fibrillation Using Transcranial Doppler Ultrasonography
Clinical Neurology and Neuroscience · 20.03.2023 · 7 (1) · 13-17
DOI: 10.11648/j.cnn.20230701.13 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Neurology and Neuroscience, online erschienen am 20.03.2023. Verfasst von Mohamed Ahmed Zaki und 1 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Warfarin with optimized international normalization ratio (INR); is significantly affect the Micro embolic signals (MES), in many studies. Non vitamin k antagonist oral anticoagulants (NOACs) are recently approved for stroke prevention in non valvular AF. In contrast to Warfarin; effect of NOACs on MES is not yet fully researched.
Aim
To determine the effect of NOACs on MES, in comparison to warfarin in non valvular AF, to reflect the potential embolization risk.
Methods
The incidence and number of MES was studied in patients with non valvular AF. Two groups in the current study; the first, patients were put on warfarin with INR levels were optimized to (2-3), and considered as a control group. The second; patients were put on NOAC (rivaroxaban, 15 mg /day). Study patients were recruited from cardiology outpatient clinics and departments (Al-Azhar University hospitals; Cairo and New Damietta, Egypt). Patients of the both groups were subjected to MES detection and counting by transcranial Doppler ultrasonography (TCD) monitoring.
Results
MES did not detected in 22.5% in study groups; no statistically significant differences between study groups. The incidence and number of MES; within the warfarin group; MES were detected in (30 patients, 75%), while within the rivaroxaban group (32 patients, 80%). The average number of MES; in group one were (11.65 ±7.20), and in group two (11.50 ±7.20), with no significant statistical difference also.
Conclusion
The effect of warfarin and NOAC use is not statistically different and Rivaroxaban is not inferior to warfarin.
Zitieren
APA
Zaki, M. A., & El-Bahnasy, H. A. K. (2023). Non Vitamin k Antagonist Oral Anticoagulation Assessment in Non Valvular Atrial Fibrillation Using Transcranial Doppler Ultrasonography. Clinical Neurology and Neuroscience, 7(1), 13-17. https://doi.org/10.11648/j.cnn.20230701.13
Vancouver
Zaki MA, El-Bahnasy HAK. Non Vitamin k Antagonist Oral Anticoagulation Assessment in Non Valvular Atrial Fibrillation Using Transcranial Doppler Ultrasonography. Clinical Neurology and Neuroscience. 2023;7(1):13-17. doi:10.11648/j.cnn.20230701.13
BibTeX
@article{Zaki2023,
author = {Zaki, Mohamed Ahmed and El-Bahnasy, Hamouda Abdel Khalek},
title = {Non Vitamin k Antagonist Oral Anticoagulation Assessment in Non Valvular Atrial Fibrillation Using Transcranial Doppler Ultrasonography},
journal = {Clinical Neurology and Neuroscience},
year = {2023},
volume = {7},
number = {1},
pages = {13--17},
doi = {10.11648/j.cnn.20230701.13}
}
EUVIMED